AfrEVacc

African-European HIV Vaccine Development Network

Objective

The project aims to develop a comprehensive network of institutional partners from Europe and Africa and use their existing data and expertise to build new capacity for HIV vaccine trials in Mozambique, South Africa and Tanzania.

Background

The African-European HIV Vaccine Development Network (AfrEVacc) is a multi-centre international three-year project funded by the European & Developing Countries Clinical Trials Partnership (EDCTP). The AfrEVacc network will undertake a pilot trial of a potential vaccine candidate in clinical sites in year 2, and the sites will be ready to participate in an efficacy trial at the end of year 3.

Beyond South-North Networking, the Afrevacc Network will greatly contribute to South-South Networking activities and to the development, acquisition and sharing of local skills and strengths.

Summary

Name: AfrEVacc: African-European HIV Vaccine Development Network
Status: Closed
Principal Investigator: Dr. J.H.H.M. van de Wijgert
Departments(s): AMC Department of Global Health
Partners: Imperial College, United Kingdom

EuroVacc Foundation

Sanofi Pasteur SA

Centre Hospitalier Universitaire Vaudois, Division of Immunology and Allergy, Switzerland

University of KwaZulu-Natal/Africa Centre for Health and Population Studies

Medical Research Council South Africa

Wits Health Consortium (Pty) Ltd trading as the Reproductive Health & HIV Research Unit (RHRU)

Institute for Medical Microbiology and Hygiene University of Regensburg

University of Munich

Mbeya Medical Research Program

Universidade Católica de Moçambique (UCM)

University of Barcelona, Institut d’Investigacions Biomedics August Pi y Sunyer (IDIBAPS)

Contact information: Project Manager: Friso Janssen

E-mail: f.janssen@aighd.org

Duration: Start date: 28 March 2008

Duration: 48 months

End date: 27 March 2012

Funded by: EDCTP
Countries: Mozambique
South Africa
Tanzania
Publications: